Physician profile
Brian Zehr
NPI 1619911005
$2,487.00
in general payments reported to CMS, 2019-2025
23 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $45.77 · 2021: $148 · 2022: $584 · 2023: $481 · 2024: $416 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.05 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $394.07 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $212.19 | 2021-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $161.76 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.39 | 2019-2023 | Ofev |
| Mallinckrodt Hospital Products INC. | $158.37 | 2020-2023 | Acthar |
| Genzyme Corporation | $139.11 | 2019-2024 | |
| Glaxosmithkline, LLC. | $122.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $116.81 | 2019 | |
| Inogen, INC. | $103.88 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols USA, LLC | $84.20 | 2019-2024 | Prolastin-C Liquid |
| Amgen INC. | $80.45 | 2023-2025 | Tezspire |
| United Therapeutics Corporation | $57.26 | 2022-2025 | Tyvaso |
| Pulmonx Corporation | $57.24 | 2024-2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $43.61 | 2022-2024 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $33.56 | 2024 | Arikayce |
| Philips North America LLC | $33.09 | 2023-2025 | Vest Therapy Und |
| Bard Peripheral Vascular, INC. | $25.37 | 2024 | |
| Electromed, INC. | $19.62 | 2025 | Smartvest |
| Csl Behring | $17.90 | 2019 | |
| Pharming Healthcare, INC. | $17.06 | 2023 | Ruconest |
| Viatris Specialty LLC | $15.08 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Zehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.